Abstract:The worldwide use of CD19 chimeric antigen receptor (CAR)-T cells has increased the response rate in patients with refractory or relapsed B-cell acute lymphoblastic leukemia. Clinical practice has become much safer with the help of immunotherapy-related toxicity management guidelines, such as the ASTCT consensus grading system. Tocilizumab and steroids are the major interventions for controlling cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New drugs and interventions for uncontrolled CRS and ICANS, including JAK1/2 inhibitors, have also been investigated. The combination of ruxolitinib and steroids effectively controlled severe CRS without impeding CAR-T cell expansion. Patients with refractory CNS3 status and CNS masses were excluded from the clinical trials because of the high risk of severe ICANS. Intracranial injections of steroids and Ommaya capsule implantation were effective. For some heavily treated patients, the difficulties in CAR-T cell manufacturing and expansion may be resolved by combination with blinatumumab. Relapse is a major concern after CAR-T therapy, and combination interventions, such as allogeneic stem cell transplantation, dual-target CAR-T cell therapies, and sequential CD19/22 CAR-T infusion, have been investigated in many centers. For T-lineage-targeted CAR-T therapies, the CAR T-cell fratricide can be overcome using many techniques. The efficacy and safety of CD7+ CAR-T cell therapy have been widely reported in recent years. A high response rate can be achieved when the immune reconstitution is prolonged. Infections, particularly viral reactivations, should be carefully monitored, as relapses are another potential issue. Switching targets and eliminating residual CD7+ CAR-T cells in the blood are key points for patients who relapse after CD7+ CAR-T cell therapy. CAR-T cell therapies for AML have not been investigated in a large-scale cohort, except for CD19-positive AML with the AML1-ETO fusion gene.

Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Chimeric Antigen Receptors for Adoptive T Cell Therapy in Acute Myeloid Leukemia.

Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia

A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia

Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Chimeric antigen receptor T cells for acute myeloid leukemia

Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Research Progress of Chimeric Antigen Receptor Modified T Cells in Treatment of Acute Myeloid Leukemia

Cooperative CAR targeting to selectively eliminate AML and minimize escape

Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia

CAR-T Cells Targeting CLL-1 As an Approach to Treat Acute Myeloid Leukemia.

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia

Honing CAR T cells to tackle acute myeloid leukemia

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia

Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models

Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML